Ireland - English - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - somatropin; somatropin - powder and solvent for solution for injection - 2.0 milligram(s) - somatropin and somatropin agonists; somatropin

Ireland - English - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - somatropin; somatropin - powder and solvent for solution for injection - 0.2 milligram(s) - somatropin and somatropin agonists; somatropin

Ireland - English - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - somatropin; somatropin - powder and solvent for solution for injection - 1.4 milligram(s) - somatropin and somatropin agonists; somatropin

United States - English - NLM (National Library of Medicine)

emd serono, inc. - somatropin (unii: nqx9kb6pcl) (somatropin - unii:nqx9kb6pcl) - somatropin 8.8 mg in 1 ml - zorbtive® is indicated for the treatment of short bowel syndrome in adult patients receiving specialized nutritional support. zorbtive® is contraindicated in patients with: - active malignancy - acute critical illness due to complications following open heart or abdominal surgery, multiple accidental trauma or acute respiratory failure [see warnings and precautions (5.2)] - active proliferative or severe non-proliferative diabetic retinopathy - hypersensitivity to somatropin or any of the excipients of zorbtive® . systemic hypersensitivity reactions have been reported with postmarketing use of somatropin products [see warnings and precautions (5.4)] risk summary there are no available data on zorbtive® use in pregnant women to inform any drug associated risks. in animal reproduction studies, no fetal harm was reported with subcutaneous administration of somatropin during the period of organogenesis in rats and rabbits at doses of approximately up to 5 and 10 times, respectively, the recommended human dos

United States - English - NLM (National Library of Medicine)

ferring pharmaceuticals inc. - somatropin (unii: nqx9kb6pcl) (somatropin - unii:nqx9kb6pcl) - somatropin 5 mg - zomacton is indicated for the treatment of pediatric patients with: - growth failure due to inadequate secretion of endogenous growth hormone (gh), - short stature associated with turner syndrome, - idiopathic short stature (iss), height standard deviation score (hsds) ≤-2.25 and associated with growth rates unlikely to permit attainment of adult height in the normal range, - short stature or growth failure in short stature homeobox-containing gene (shox) deficiency, - short stature born small for gestational age (sga) with no catch-up growth by 2 years to 4 years of age. zomacton is indicated for the replacement of endogenous gh in adults with gh deficiency. zomacton is contraindicated in patients with: - acute critical illness after open heart surgery, abdominal surgery or multiple accidental trauma, or those with acute respiratory failure due to the risk of increased mortality with use of pharmacologic doses of somatropin [see warnings and precautions (5.1)] . - pediatric patients with prader-willi s

United States - English - NLM (National Library of Medicine)

anumed international llc - somatropin (unii: nqx9kb6pcl) (somatropin - unii:nqx9kb6pcl) - somatropin 6 [hp_c] in 200 ml - improve sleep, increase energy, anti-aging benefits, increase lean muscle reduce fat, increase lean mass, improve sleep, increase energy, reduce nervousness, decrease stress and anxiety, improve sense of well-being

Israel - English - Ministry of Health

ferring pharmaceuticals ltd - somatropin - powder and solvent for solution for injection - somatropin 10 mg - somatropin - somatropin - children :short stature due to inadequate or failed secretion of pituitary growth hormone or turner's syndrome. short stature in children with renal insufficiency.

Israel - English - Ministry of Health

novo nordisk ltd., israel - somatropin - solution for injection - somatropin 10 mg / 1 ml - somatropin - somatropin - children: * short stature due to inadequate or failed secretion of pituitary growth hormone or turner`s syndrome. * short stature in children with renal insufficiency. * growth disturbance (current height sds < - 2.5 and parental adjusted height sds < - 1) in short children born small for gestational age (sga) with a birth weight and/or length below - 2 sd who failed to show catch-up growth (hv sds < during the last year) by 4 years of age or later.* children with short stature associated with noonan syndrome.adults: treatment of adults with hypothalamic-pituitary disease resulting from organic disease or pituitary tumors treated medically surgically or radiotherapy or patients with childhood onset of g.h. deficiency.

Israel - English - Ministry of Health

novo nordisk ltd., israel - somatropin - solution for injection - somatropin 10 mg / 1.5 ml - somatropin - somatropin - children: * short stature due to inadequate or failed secretion of pituitary growth hormone or turner`s syndrome. * short stature in children with renal insufficiency. * growth disturbance (current height sds < - 2.5 and parental adjusted height sds < - 1) in short children born small for gestational age (sga) with a birth weight and/or length below - 2 sd who failed to show catch-up growth (hv sds < during the last year) by 4 years of age or later.* children with short stature associated with noonan syndrome.adults: treatment of adults with hypothalamic-pituitary disease resulting from organic disease or pituitary tumors treated medically surgically or radiotherapy or patients with childhood onset of g.h. deficiency.

Australia - English - Department of Health (Therapeutic Goods Administration)

scigen australia pty ltd - somatropin, quantity: 3.3 mg/ml - injection - excipient ingredients: mannitol; benzyl alcohol; poloxamer; water for injections; dibasic sodium phosphate heptahydrate; monobasic sodium phosphate dihydrate; sodium hydroxide; phosphoric acid - scitropin a is intended for long term treatment of children (above three years of age with growth disturbance due to insufficient secretion of pituitary growth hormone; growth disturbance associated with gonadal dysgenesis (turner's syndrome); & growth disturbance associated with chronic renal insufficiency.